Recent advances in the biology of PTCLs have led to the identification of new targets, and to the establishment of biomarker-driven treatments such as BV for ALCL and ALK inhibitors for ALK+ ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.